GREEN PLANET MICROCAPS
ESG MICROCAP SPECIALISTS
Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better
TOMORROW'S WINNERS TODAY
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest
Propanc Biopharma PRP Cancer Drug Could Boost Chemo and Immunotherapy Drug Sales
-
Chemo and immunotherapy are the prevailing drug treatments for cancer
-
There is supportive scientific evidence that Propanc’s PRP can potentially make chemo and immunotherapy drugs work better by converting cancer cells back towards normal healthy cell behaviors
-
Improved efficacy would likely create strong demand for PRP by first adopter chemo and immunotherapy drug makers
-
Propanc’s PRP demonstrated compelling results where 41% of 46 patients with broad spectrum of late-stage cancers had a survival time significantly longer than expected
-
Propanc’s PRP targets over 80% of all cancers
-
Propanc’s PRP does not kill cancer cells – it converts them back towards normal healthy cell behavior so that they die naturally
-
A recent Scientific Reports paper about Propanc’s PRP was published on the National Institute of Health site and has generated significant interest by the scientific and medical community
-
Propanc shares are sub-penny with a total market cap of about $300,000 and the cancer therapeutics market is well over $200 billion and climbing fast
Propanc Biopharma, Inc. (PPCB: OTC) owns 93 patents for their promising new cancer treatment drug called, ‘PRP’. Propanc’s PRP is a novel treatment that has been receiving significant interest by scientists and medical professionals in recent peer-reviewed papers published on the prestigious site of the National Institute of Health (NIH).
The scientific paper about Propanc’s new approach to treating cancer was recently published in Scientific Reports and in only one month of August 2024, it achieved a record 4,500 reads and 10 citations. This level of interest by the scientific and medical communities may foretell that a potential new breakthrough in cancer treatment could be on the horizon.
PRP™ is a type of pancreatic proenzyme therapy that aims to improve the outcomes of cancer treatment by making cancer cells more sensitive to chemotherapy and immunotherapy.
The mechanism of action behind Propanc PRP is that pancreatic enzymes can help break down the protective barriers around cancer cells, allowing chemotherapy and immunotherapy to penetrate more effectively and target the cancer cells more directly.
This could potentially lead to better results from chemotherapy and immunotherapy and possibly reduce some of the side effects associated with treatment.
Click on the image below to see how PRP works
Promising Results
Results of a Compassionate Use Study using proenzyme therapy as a stand-alone treatment were compelling. 41% of 46 patients with a broad spectrum of late-stage cancers had a survival time significantly longer than expected.
Need and Market Size
The market for chemo and immunotherapy is over $200 billion per year and growing rapidly. The list below indicates fierce competition between drug makers and if PRP demonstrates in upcoming clinical trials that it improves efficacy of chemo and immunotherapy drugs, the first adopters of PRP may have the potential to gain substantially increased market share over their competition.
A partial list of some better-known chemo and immunotherapy makers and their drugs is
-
Roche (RHBBY: OTCQX): Herceptin (trastuzumab) and Avastin (bevacizumab)
-
Pfizer (PFE: NYSE): Ibrance (palbociclib) and Doxil (doxorubicin hydrochloride liposome injection
-
Novartis (NVS: NYSE): Kisqali (ribociclib) and Kymriah (tisagenlecleucel) Merck (MRK: NYSE) Keytruda (pembrolizumab)
-
Bristol-Myers Squibb (BMY: NYSE): Opdivo (nivolumab) and Yervoy (ipilimumab) Revlimid (lenalidomide) and Pomalyst (pomalidomide)
-
Johnson & Johnson (JNJ: NYSE): Zytiga (abiraterone) and Imbruvica (ibrutinib)
-
AstraZeneca (AZN: NYSE) Tagrisso (osimertinib) and Lynparza (olaparib)
-
Eli Lilly (LLY: NYSE) Alimta (pemetrexed) and Cyramza (ramucirumab)
-
Amgen (AMGN: NASD) Blincyto (blinatumomab) and Xgeva (denosumab)
-
Gilead Sciences (GILD: NASD): Yescarta (axicabtagene ciloleucel)
-
AbbVie (ABBV: NYSE): Imbruvica (ibrutinib)
-
Sanofi (SNY: NASD): Taxotere (docetaxel) and Eloxatin (oxaliplatin)
-
Takeda (TAK: NYSE): Ninlaro (ixazomib) and Velcade (bortezomib)
Supporting Evidence that PRP May Reduce Chemo Resistance
December 13, 2023, Propanc Biopharma, Inc. announced that the Company’s joint researcher, Mrs. Belén Toledo Cutillas, has commenced an internship at the Cancer Center Amsterdam – vUMC (University Medical Centers). In addition to Propanc Biopharma providing the financial resources to develop PRP, funding from two international grants has enabled Mrs. Toledo to join the Molecular Oncology Laboratory at the Cancer Center Amsterdam. Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
"Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer. But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer. It is key to identify new drugs that could reduce chemoresistance and thus combat tumors with existing treatments," said Mrs. Toledo. The preclinical research undertaken by Mrs. Toledo at the Cancer Center Amsterdam focuses on the effects of pancreatic proenzyme formulation (PRP) on a panel of chemoresistant cancer cell lines that had previously been established in Professor Giovanetti’s lab.
"We wanted to evaluate the effect of PRP in the widest range of pancreatic cancer cell lines to gain a better idea how this treatment may affect actual tumors," said Mrs. Toledo. "So far, we have obtained very promising results. PRP seems not only to reduce chemoresistance of pancreatic tumor cells, but also appears to alter the tumor microenvironment."
Dr Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer said, "We are pleased to continue to drive success through our joint research partners, and Belén’s investigation into the effects of PRP as a chemosensitizing agent has significant implications for the planned clinical development of PRP as a novel therapy for the treatment and prevention of metastatic cancer. Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer. We look forward to investigating the clinical effects of PRP in patients as we progress with future planned clinical trials, where an opportunity for a combinatorial therapeutic strategy may be uncovered to treat resistant tumors."
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.
Challenging but Promising Future for Propanc’s PRP
With a $200 billion market that is growing rapidly and the potential to improve the efficacy of the drugs making up this market, Propanc Biopharma, Inc. stands out with a potentially game-changing drug, 93 patents, and a total market cap of under $300 thousand.
Seasoned and successful biotech investors know and understand the potential risks of dilutive future fundings, clinical trials, and market acceptance, but sometimes the rewards can far outweigh the risks.
Early results appear to warrant a very close look at what could be a significant breakthrough in cancer treatment and if Propanc is able to succeed in clinical trials, PRP could be a major advancement in the treatment of cancer.
Legal Disclosures and Disclaimers
Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.
Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.
Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.
Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.
Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from. Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.
Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.